EN DE
Watch Nurix Therapeutics Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Nurix Therapeutics Inc (NRIX) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Nurix Therapeutics Inc stock $13.31, price $14.73, that is 9.6% below the price, quality 34 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · ISIN US67080M1036

NT Nurix Therapeutics Inc logo Thin data Nov 17, 2026

Nurix Therapeutics Inc

NRIX · US

Expensive (fair value 10% below the price) and weak company, but rising price: meets 1 of 3 rules.

Get notified free when this changes
Rising price (uptrend) 
Highly profitable · 42.0% net margin (TTM) 
Generates free cash flow over the last twelve months 
Ranks above peers (8/11) 
Revenue last quarter +84% vs. a year ago. 
Expensive Growth (revenue 5y +36.3 %/yr in USD) 
Wide moat 68/100 · thin data
Insiders sold $3.7M (6M) 
Fair value $13.31 · Overvalued 
Quality 34/100 
Recent news very negative 
Thin data 
Estimate
Watch Nurix Therapeutics Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$36.69 $4.25 Fair Value $13.31 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 17, 2026.

How to read this chart

60‑month range $4.25 – $36.69 · fair‑value band $9.98 – $16.64 · the $14.73 price screens above the $13.31 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 17, 2026.

Follow Nurix Therapeutics in your weekly email

Every Wednesday you see whether Nurix Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases.

Show moreShow less

The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications.

It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases.

The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates.

The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.

Stock analysis

Nurix Therapeutics Inc (NRIX) currently trades at $14.73, while our estimate is $13.31, 10% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $9.98 (bear) to $16.64 (bull), the price of $14.73 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 34/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Nurix Therapeutics Inc reported revenue of $84.0M in FY2025 versus $29.8M in FY2021, a compound +29.6%/yr. Reported net income was −$264M in FY2025.

Key figures

Market cap $2.9B Mid · P/E ratio 6.1 · P/S ratio 2.24 · EPS (TTM) $2.43 · Net margin 42.0% · Return on equity 44.0% · Return on assets (EBIT) −37.2% (5-year average) · Operating margin 83.1%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 68 out of 100 (low confidence).

What moves the price

The share trades about 47% below its 52-week high and 16% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −10%, NRIX screens richer than that median.

Fair Value

Bear $9.98 Fair Value $13.31 Bull $16.64
Price $14.73 · Downside -9.6%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 34/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 3
How much profit the company makes from its sales and capital
Quality Growth 74
Are margins and returns getting better?
Cashflow 10
Do the profits arrive as real cash?
Financial strength 100
Debt, balance sheet and risk of trouble
Investment 9
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 43
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 34
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 4 officers or directors sold shares worth $3.7M and none bought.

  • SaleHans van HouteChief Financial Officer7× since Jan 30, 2026: 35,313 shares, avg. $18.84$665,447Nov 4, 2026
  • SaleChristine RingChief Legal Officer19× since Nov 24, 2025: 197,626 shares, avg. $19.67$3.9MNov 3, 2026
  • SaleGwenn HansenChief Scientific Officer9× since Jan 30, 2026: 34,130 shares, avg. $22.20$757,795Nov 2, 2026
  • SaleJulia P GregoryDirector22,583 shares at $23.40$528,528Oct 14, 2026

Plus 17 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+54.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+29.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+36.3%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−364.7% (2020) → −340.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

NRIX screens overvalued: fair value 10% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Earlier news

News mood ⓘNews mood, the average tone of recent news (91 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Very negative
Recent news coverage is unusually downbeat.

Compare Nurix Therapeutics Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 847 stocks

Beats the industry median on 8/11 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 34 · Below median
Fair Value upside −9.6% · Above median
Profitability
Return on equity (12 months) 44.0% · Top 25%
Return on assets −38.4% · Below median
Net margin (12 months) 42.0% · Top 25%
Operating margin (12 months) 83.1% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) 84.3% · Top 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/E (12 months) 6.1× · Cheapest 25%
P/B 5.43× · Priciest 25%
P/S (12 months) 4.17× · Cheaper than median
EV/EBITDA 9.0× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)21 · sector 0
FUTURE (revenue growth)100 · sector 36
PAST (return on equity)100 · sector 0
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 21

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $952.40 $1,275 +34% vs NRIX
Vertex Pharmaceuticals Incorporated VRTX $537.79 $592.46 +10% vs NRIX
Samsung Biologics Co 207940 1,423,000 KRW 1,552,100 KRW +9% vs NRIX
argenx SE ARGX $950.95 $908.40 −4% vs NRIX
CSL Limited CSL A$199.55 A$186.49 −7% vs NRIX
Moderna, Inc MRNA $215.27 $135.64 −37% vs NRIX
BeOne Medicines AG 6160 HK$249.40 HK$152.92 −39% vs NRIX
Revolution Medicines, Inc RVMD $166.87 $88.78 −47% vs NRIX
Celltrion, Inc 068270 214,500 KRW 74,945 KRW −65% vs NRIX
Royalty Pharma plc RPRX $68.53 $19.01 −72% vs NRIX

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Nurix Therapeutics Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Nurix Therapeutics Inc Fair Value". https://www.fairvalue-calculator.com/stock/NRIX

Frequently asked questions

Is Nurix Therapeutics Inc (NRIX) overvalued or undervalued?
As of Nov 17, 2026, our estimate of fair value is $13.31 versus a price of $14.73, about 10% lower (overvalued).
What is the fair value of NRIX?
Our estimate for Nurix Therapeutics Inc is $13.31 (as of Nov 17, 2026), built from audited fundamentals. The current price: $14.73.
What is the quality score of NRIX?
Nurix Therapeutics Inc has a Quality Score of 34/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Nurix Therapeutics Inc (NRIX)?
Our calculated price target is the estimate of $13.31 (as of Nov 17, 2026). Cautious scenario $9.98, optimistic scenario $16.64. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Nurix Therapeutics Inc stock forecast for 2026?
Our estimate puts fair value at $13.31, about 10% lower versus a price of $14.73 (overvalued). Cautious scenario $9.98, optimistic scenario $16.64. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Nurix Therapeutics Inc (NRIX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Nurix Therapeutics Inc it is $13.31 per share (as of Nov 17, 2026), against a price of $14.73.
Is Nurix Therapeutics Inc stock overvalued or undervalued in 2026?
As of Nov 17, 2026, NRIX trades above its calculated fair value: price $14.73, fair value $13.31, a gap of about −10% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of NRIX?
No. The price is what the market pays today ($14.73); the fair value is what the company's own numbers justify ($13.31). For Nurix Therapeutics Inc the two are $1.42 per share apart. That gap is exactly why we show both numbers side by side.
How much is Nurix Therapeutics Inc worth?
The market values Nurix Therapeutics Inc at about $2.9B (market capitalisation, as of Nov 17, 2026). Per share that is $14.73; our models calculate a fair value of $13.31 per share.
What do the bullish and bearish scenarios say about NRIX?
Our models span a range for Nurix Therapeutics Inc: cautious scenario $9.98, base $13.31, optimistic $16.64 per share (as of Nov 17, 2026, price $14.73). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of NRIX?
Nurix Therapeutics Inc trades at a price-to-earnings ratio of 6.1 (as of Nov 17, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $13.31 is built from several models across several years. Other multiples: P/B 5.4, P/S 4.2, EV/EBITDA 9.0.
How solid is the balance sheet of Nurix Therapeutics Inc (NRIX)?
Balance-sheet figures for Nurix Therapeutics Inc (as of Nov 17, 2026): return on equity 44.0%. They feed the Quality Score of 34/100, which measures business quality independently of the share price.
How far is NRIX from its 52-week high?
Nurix Therapeutics Inc trades at $14.73, about 47% below its 52-week high of $27.79 and 16% above the low of $12.68 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of $13.31 is for.
Which stocks are comparable to Nurix Therapeutics Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Nurix Therapeutics Inc stock attractive at the current price?
The data as of Nov 17, 2026: price $14.73, calculated fair value $13.31 (−10%), Quality Score 34/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Nurix Therapeutics Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Nurix Therapeutics Inc (NRIX)?
The closing price on Nov 16, 2026 was $14.73. Our estimate is $13.31, about 10% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Nurix Therapeutics Inc right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits in the upper half of our model range, so the margin of safety is thin. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of Nurix Therapeutics Inc

How large is the market capitalisation of Nurix Therapeutics Inc (NRIX)?
The market capitalisation of Nurix Therapeutics Inc is $2.9B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Nurix Therapeutics Inc (NRIX)?
The price-to-sales ratio of Nurix Therapeutics Inc is 2.24 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Nurix Therapeutics Inc (NRIX)?
Earnings per share at Nurix Therapeutics Inc are $2.43 (price ÷ EPS = P/E 6.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Nurix Therapeutics Inc (NRIX)?
The net margin of Nurix Therapeutics Inc is 42.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Nurix Therapeutics Inc (NRIX)?
The return on equity (ROE) of Nurix Therapeutics Inc is 44.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Nurix Therapeutics Inc (NRIX)?
On an EBIT basis the return on assets of Nurix Therapeutics Inc is −37.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Nurix Therapeutics Inc (NRIX)?
The operating margin of Nurix Therapeutics Inc is 83.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Nurix Therapeutics Inc (NRIX)?
Revenue at Nurix Therapeutics Inc is growing 84.3% versus a year earlier (3y avg +29.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Nurix Therapeutics Inc (NRIX) generate?
The free cash flow of Nurix Therapeutics Inc is −$263M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Nurix Therapeutics Inc (NRIX) hold?
Nurix Therapeutics Inc holds more cash than debt, $191M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Nurix Therapeutics Inc in the live analysis

One click puts Nurix Therapeutics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.